Dr. Hao Yu 于浩
Chief Physician
Gynecologic Oncology, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of benign and malignant gynecologic tumors, including cervical, endometrial, ovarian, vulvar, and vaginal cancers. Specializes in complex, recurrent, and metastatic cases requiring major reconstructive and exenteration procedures.
Dr. Yu is Director of the Gynecologic Oncology Ward at Shandong Cancer Hospital, Professor, and graduate supervisor. Holding a PhD in Obstetrics and Gynecology from Shandong University and a postdoctoral degree in Oncology, Dr. Yu has over ten years of experience in comprehensive gynecologic cancer treatment.
Professional roles
- Chair, Gynecologic Oncology Expert Committee, Shandong Clinical Oncology Society
- Vice Chair, Youth Committee of Gynecologic Oncology Branch, Shandong Anti-Cancer Association
Name order: in Chinese the family name comes first (Yu Hao). Papers usually list the name as Hao Yu or Yu H.
Selected publications
34 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2026 (senior author): Invasive stratified mucin-producing carcinoma of the cervix: a report of 34 cases of immunohistochemical and clinicopathological findings. PubMed 41847703
- Int J Med Sci, 2025 (first author): Oncogenic and Immunological Roles of FRS2 and its Potential Value in Retroperitoneal Liposarcoma: from Bioinformatics Analysis to Clinicopathological Evidence. PubMed 40225873
- Int J Genomics, 2024 (senior author): Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 3 Expression and Its Correlation with Prognosis and Growth of Serous Ovarian Cancer: Correlation of DYRK3 with Ovarian Cancer Survival. PubMed 38529261
- Cancer Invest, 2024 (senior author): A 15-Inflammation-Related Gene Signature Predicts the Prognosis of Patients With Pancreatic Ductal Adenocarcinoma. PubMed 38616304
- Curr Stem Cell Res Ther, 2024 (senior author): Potential Druggability of Mesenchymal Stem/Stromal Cell-derived Exosomes. PubMed 38523514
- Front Biosci (Landmark Ed), 2023 (senior author): Molecular Subtypes of Ovarian Cancer Based on Lipid Metabolism and Glycolysis Reveals Potential Therapeutic Targets. PubMed 37919068
- Cell Biol Int, 2023 (senior author): Spatio-temporal metabolokinetics and therapeutic effect of CD106(+) mesenchymal stem/stromal cells upon mice with acute lung injury. PubMed 36490221
- Invest New Drugs, 2020 (senior author): Phase II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients. PubMed 31637668
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion